Page last updated: 2024-10-31

metyrapone and Abnormality, Heart

metyrapone has been researched along with Abnormality, Heart in 2 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Research Excerpts

ExcerptRelevanceReference
"Medical therapy can be used to treat Cushing syndrome and can result in improvement in the cardiovascular pathology."1.72Cushing syndrome as a failed cardiac screen in a patient with McCune-Albright syndrome: a case report. ( Al Zubeidi, H; Diaz-Thomas, A; Foster, C, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Foster, C1
Al Zubeidi, H1
Diaz-Thomas, A1
Gács, G1
Horn, G1
Ortwein, V1

Other Studies

2 other studies available for metyrapone and Abnormality, Heart

ArticleYear
Cushing syndrome as a failed cardiac screen in a patient with McCune-Albright syndrome: a case report.
    Journal of medical case reports, 2022, Sep-15, Volume: 16, Issue:1

    Topics: Cushing Syndrome; Dexamethasone; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits;

2022
Pituitary-adrenal function in congenital heart disease.
    Acta paediatrica Academiae Scientiarum Hungaricae, 1971, Volume: 12, Issue:3

    Topics: 17-Ketosteroids; Adolescent; Adrenal Glands; Age Factors; Child; Child, Preschool; Cyanosis; Growth

1971